DNA & Synthetic Conjugate Vaccines Travel & Edible Vaccines
Conjugate antibodies, made up of a bacterial polysaccharide antigen cross-connected to a bacterial protein, are among the best immunizations accessible today to avert bacterial diseases, for example, pneumococcal and meningococcal contaminations. Conjugate antibodies against bacterial pathogens with a substantial number of serotypes, for example, Streptococcus pneumoniae, generally cover just a few the current strains. Another recombinant DNA-based assembling innovation has been created to avert genuine bacterial diseases. This innovation can possibly prompt antibodies against unmanageable pathogens, for example, S. aureus and Shigella species and to rearrange and enhance the proficiency of creating complex conjugate antibodies.
- Adjuvant
- DNA vaccination
- Prime-boost Vaccination
- Reverse Vaccinology
- DNA Immunization
- Pneumococcal Conjugate Vaccine
Related Conference of DNA & Synthetic Conjugate Vaccines Travel & Edible Vaccines
21th International Conference on Allergic Diseases and Clinical Immunology
13th World Congress and Exhibition on Antibiotics and Antibiotic Resistance
DNA & Synthetic Conjugate Vaccines Travel & Edible Vaccines Conference Speakers
Recommended Sessions
- Immunopathogenesis
- Allergy, Asthma, and Immunology
- Animal & Plant-Derived Vaccines
- Child immunization and Vaccination Viral Immunology
- Clinical and Diagnostic Immunology
- Current research, and future challenges in vaccines
- DNA & Synthetic Conjugate Vaccines Travel & Edible Vaccines
- Geriatric Immunizations
- Human Vaccines-Infectious & non-Infectious
- Immunoinformatics
- Immunological Disorders
- Immunotoxicology
- Neuroendocrine Immunology
- Onco Immunology
- Paediatric Vaccinations
- Pathology and Immunology
- Psychoneuroimmunology
- Stem cell Immunology
- Vaccine & Immunization
- Vaccines against Drugs
Related Journals
Are you interested in
- Antibiotic Prophylaxis - Antibiotics 2026 (UK)
- Antibiotic Resistance: Opportunities and Challenges - Antibiotics 2026 (UK)
- Antibiotic-resistant Bacterial infections - Antibiotics 2026 (UK)
- Antibiotics - Antibiotics 2026 (UK)
- Antibiotics for Various Diseases and Infections - Antibiotics 2026 (UK)
- Antibiotics: In Pregnancy and Lactation - Antibiotics 2026 (UK)
- Antimicrobial Peptides - Antibiotics 2026 (UK)
- Antimicrobial Therapy - Antibiotics 2026 (UK)
- Clinical Trials of Antibiotics - Antibiotics 2026 (UK)
- Current Research in Antibiotic Resistance - Antibiotics 2026 (UK)
- Developing Alternatives to Antibiotics - Antibiotics 2026 (UK)
- Drug Discovery and Novel Delivery Technologies - Antibiotics 2026 (UK)
- Immunology & Vaccines - Antibiotics 2026 (UK)
- Infectious Diseases - Antibiotics 2026 (UK)
- Mechanisms and Evolution of Antibiotic Resistance - Antibiotics 2026 (UK)
- Micro Organisms in Recent Drug Discovery - Antibiotics 2026 (UK)
- Microorganisms Producing Antibiotics - Antibiotics 2026 (UK)
- Modern Antibiotics for Various Diseases and Infections - Antibiotics 2026 (UK)
- New antibiotics and non-antibiotic approaches - Antibiotics 2026 (UK)
- Pharmacokinetics and Pharmacodynamics of Antimicrobial Drugs - Antibiotics 2026 (UK)
- Pharmacology & Toxicology - Antibiotics 2026 (UK)
- Prevention and Control of Antibiotic Resistance - Antibiotics 2026 (UK)
- The Next Generation Approach of Antibiotics - Antibiotics 2026 (UK)
